Trending News
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- This event has passed.
Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2019
November 15, 2019 - November 16, 2019
Nationally and internationally renowned faculty will provide a state-of-the-art update on the latest treatment options for patients with hepato-pancreatico-biliary cancers. The program is designed to provide a multidisciplinary overview on the importance of early diagnosis and treatment considerations, including surgery and new pharmacological agents, and how to incorporate these treatment options into clinical practice.
13.00 AMA PRA Category 1 Credits™ – maximum
13.00 ANCC contact hours